Endra Life Sciences touts preliminary TAEUS liver fat analysis study data

Endra Life Sciences today reported preliminary results from the first-in-man feasibility study of its Thermo Acoustic Enhanced Ultrasound System exploring its ability to measure and analyze liver fat. The TAEUS platform is designed to allow for the visualization of human tissue composition, function and temperature at a cheaper cost than computed tomography or magnetic resonance imaging and provided at the point-of-care, the Ann Arbor, Mich.-based company said. Preliminary data came from 25 subjects analyzed with the TAEUS platform as compared with quantitative MRI fat fraction measurements and other indicators including Body Mass Index and abdominal fat thickness as measured by traditional ultrasound. Results from the trial indicated that 21 subjects in the study had less than 6% liver fat fraction as assessed by MRI, classified in the healthy or normal range, while the other four subjects were found to have between 8% and 22.4% fat fraction, which is classified as mild non-alcoholic fatty liver disease. Study investigators said that the correlation between thermoacoustic measurements of Endra’s reference designed and the percent fat fraction as measured by MRI had an R2 of 0.61 with a standard error of the mean of 2.98%. Correlations between BMI with MRI fat fraction were only 0.19, while the correlation of abdominal fat thickness analyzed via ultrasound and MRI fat fraction was 0.31, the company said. Endra said that some subjects in the trial with ‘mild’...
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Imaging endralifesciences Source Type: news

Related Links:

We studied the effects of dipeptidyl peptidase 4 (DPP4) inhibitor linagliptin on the expression of apoptosis regulator proteins Bcl-2 and Bad in the liver ofdb/db mice with genetically determined obesity and type 2 diabetes mellitus. The mice received daily linagliptin or saline (placebo) by gavage from week 10 to week 18 of life. In the liver of non-treated mice, the area positively stained for Bad was greater than the area of Bcl-2 expression, which created the conditions for apoptosis activation in liver at this age. Administration of linagliptin decreased Bad stained area and increased Bcl-2 stained area in the liver c...
Source: Bulletin of Experimental Biology and Medicine - Category: Biology Source Type: research
Publication date: Available online 21 June 2019Source: Nutrition, Metabolism and Cardiovascular DiseasesAuthor(s): M.L. Erickson, J.M. Haus, S.K. Malin, C.A. Flask, A.J. McCullogh, J.P. KirwanAbstractBackground and aimsNonalcoholic fatty liver disease (NAFLD) is characterized by excessive hepatic fat accumulation. Increased hepatic saturated fats and decreased hepatic polyunsaturated fats may be particularly lipotoxic, contributing to metabolic dysfunction. We compared hepatic lipid subspecies in adults with and without NAFLD, and examined links with hallmark metabolic and clinical characteristics of NAFLD.Methods and resu...
Source: Nutrition, Metabolism and Cardiovascular Diseases - Category: Nutrition Source Type: research
This study demonstrated the anti-tumor effects of berberine and its possible mechanism, providing a potential drug for treating NASH-HCC. PMID: 31217846 [PubMed]
Source: American Journal of Translational Research - Category: Research Tags: Am J Transl Res Source Type: research
AbstractPurposeElevated copeptin, a vasopressin marker, is linked to metabolic disease, and obese rats with low-vasopressin concentration had a decreased risk of liver steatosis. We here investigated the association between copeptin and nonalcoholic fatty liver disease (NAFLD) and possible differences in copeptin concentration between ethnicities.MethodsIn this cross-sectional study of 361 South Africans (n = 172 African black, 189 = Caucasian) with a mean age of 45 years and 45% men, plasma copeptin was measured and associated with NAFLD according to a validated fatty liver index accounting for...
Source: Endocrine - Category: Endocrinology Source Type: research
Authors: Alswat KA, Fallatah HI, Al-Judaibi B, Elsiesy HA, Al-Hamoudi WK, Qutub AN, Alturaify N, Al-Osaimi A Abstract Non-alcoholic fatty liver disease (NAFLD) is a major national and international health burden. It is one of the most common liver diseases worldwide and the most common cause of abnormal liver enzymes in many developed countries. Non-alcoholic fatty liver disease is also known as an important cause of cryptogenic cirrhosis and second leading cause for liver transplantation. It is commonly associated with metabolic syndrome. Non-alcoholic steatohepatitis (NASH) is the progressive phenotype of NAFLD. ...
Source: Saudi Medical Journal - Category: Middle East Health Tags: Saudi Med J Source Type: research
CONCLUSIONS: Results from ongoing prospective studies on the effects of biologics on markers of systemic inflammation in patients with psoriasis will strengthen the clinical evidence base that can be used to inform treatment decisions for patients with moderate-to-severe psoriasis. PMID: 31225638 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research
Conclusions: This study demonstrates that consumers of SSBs are at significantly increased risk of NAFLD, and the consumption of SSBs has a dose-dependent effect on the risk of NAFLD. The findings of this study strengthen the evidence base for healthy dietary patterns and are meaningful for the primary prevention of NAFLD.
Source: International Journal of Environmental Research and Public Health - Category: Environmental Health Authors: Tags: Article Source Type: research
Nonalcoholic fatty liver disease (NAFLD) is characterized by excessive hepatic fat accumulation. Increased hepatic saturated fats and decreased hepatic polyunsaturated fats may be particularly lipotoxic, contributing to metabolic dysfunction. We compared hepatic lipid subspecies in adults with and without NAFLD, and examined links with hallmark metabolic and clinical characteristics of NAFLD.
Source: Nutrition, Metabolism, and Cardiovascular Diseases : NMCD - Category: Nutrition Authors: Source Type: research
Authors: Abenavoli L, Milanović M, Milić N, Luzza F, Giuffrè AM Abstract Introduction: Non-alcoholic fatty liver disease (NAFLD) is estimated to affect 25% of adult people worldwide. Nowadays, there is no definite treatment for NAFLD. International guidelines define an approach based on lifestyle changes, included a health alimentary regimen. The Mediterranean diet (MD) represents the gold standard in preventive medicine, probably due to the harmonic combination of many elements with antioxidant and anti-inflammatory properties. Its prescription is also recommended in patients with NAFLD. Olive oil, as par...
Source: Expert Review of Gastroenterology and Hepatology - Category: Gastroenterology Tags: Expert Rev Gastroenterol Hepatol Source Type: research
Publication date: Available online 20 June 2019Source: Progress in Neuro-Psychopharmacology and Biological PsychiatryAuthor(s): Javier Vázquez-Bourgon, Víctor Ortiz-García de la Foz, Irene Suarez-Pereira, Paula Iruzubieta, María Teresa Arias-Loste, Esther Setién-Suero, Rosa Ayesa-Arriola, Marcos Gómez-Revuelta, Javier Crespo, Benedicto Crespo FacorroAbstractIntroductionIncreased incidence of obesity and excess weight lead to an increased incidence of non-alcoholic fatty liver disease (NAFLD). Recent evidence indicates a protective effect of cannabis consumption on weight gain and r...
Source: Progress in Neuro Psychopharmacology and Biological Psychiatry - Category: Psychiatry Source Type: research
More News: Alcoholism | Clinical Trials | CT Scan | Fatty Liver Disease (FLD) | Liver | Liver Disease | Medical Devices | MRI Scan | Non-alcoholic Fatty Liver Diseases (NAFLD) | Study | Ultrasound | Urology & Nephrology | USA Health